60 Degrees Pharmaceuticals, Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. 60 Degrees Pharmaceuticals, Inc. (SXTP) is a specialty pharmaceutical company focused on the development and marketing of medicines for infectious diseases. Its lead product, ARAKODA® (tafenoquine), is FDA-approved for malaria prevention. The company is currently developing programs for tick-borne, fungal, and viral diseases, including a Phase II clinical study for chronic babesiosis.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Product Revenues | $437,602 | $135,293 | $702,086 | $365,939 |
| Research Revenues | $90,960 | $12,818 | $390,630 | $43,177 |
| Net Revenue (Loss) | $(9,128) | $36,424 | $431,703 | $142,428 |
| Gross Profit (Loss) | $(100,088) | $23,606 | $41,073 | $99,251 |
| Net Loss (Attributable to 60P) | $(2,316,324) | $(2,159,785) | $(5,926,599) | $(5,902,070) |
| Cash and Cash Equivalents | $4,115,779 (as of Sept 30, 2025) | |||
| Total Debt (SBA EIDL) | $153,764 (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Product revenues increased 223% in Q3 2025 compared to Q3 2024, driven by refilling the U.S. supply chain after a Q2 stockout and increased sales volume (14% increase in box equivalents). Research revenues surged 610% due to a new contract with the U.S. Army Medical Materiel Development Activity (USAMMDA).
- Gross Margin Compression: The company reported a gross loss of $(100,088) in Q3 2025, a significant deterioration from a gross profit of $23,606 in Q3 2024. This was primarily caused by $436,561 in inventory write-downs for expiring raw materials used to validate a new production method. Management states this is a non-recurring event.
- Operating Expenses: Total operating expenses increased 7.5% in Q3 2025. General and Administrative (G&A) expenses rose 24% due to higher sales, advertising, and investor outreach costs. Research and Development (R&D) expenses decreased 13.9% year-over-year, largely due to the absence of a $600,000 non-cash share-based payment charge recognized in Q3 2024.
- Capital Raises: The company completed three equity offerings in 2025 (January, February, and July), raising approximately $6.0 million in net proceeds. The July 2025 offering alone raised ~$4.3 million.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for one year from the filing date. While cash balances increased to ~$4.1 million due to recent financing, the company estimates funds will sustain operations only through March 31, 2026, assuming no additional capital raises.
- Outlook: The company plans to fund operations through further equity or debt financing. It is seeking a Minor Use Minor Species (MUMS) designation for canine babesiosis and has announced a partnership with the Icahn School of Medicine for a Phase II babesiosis trial.
- Derivative Liabilities: The company recorded a loss of $21,103 in Q3 2025 related to the change in fair value of derivative liabilities (contingent milestone payments to Knight Therapeutics). Total derivative liabilities stood at $797,275 as of September 30, 2025.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, citing a lack of full-time in-house technical personnel, inadequate segregation of duties, and insufficient accounting staff.
Investor Verification Checklist
- Inventory Write-downs: Verify the non-recurring nature of the $436k inventory write-down and the timeline for replacing short-dated inventory (expected Q2 2026).
- Cash Runway: Confirm the accuracy of the "March 31, 2026" liquidity estimate given the high burn rate (~$5.2M cash used in operations YTD).
- Customer Concentration: Note that 80% of Q3 product revenue came from a single U.S. distributor and 13% from another; assess dependency risks.
- Dilution Risk: Review the impact of the July 2025 offering and outstanding warrants (over 7.5 million warrants outstanding) on future share count and dilution.
- Internal Control Remediation: Monitor progress on remediation plans for the disclosed material weaknesses in financial reporting controls.